DDInter1042 DDInter1382
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.
Palonosetron {u} (Compound) resembles {v} (Compound) Praziquantel
Palonosetron {u} (Compound) binds {v} (Gene) HTR3A
Palonosetron {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin 3 Receptor Antagonists
Palonosetron {u} (Compound) causes {v} (Side Effect) Malnutrition
Palonosetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Palonosetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ezogabine
Palonosetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluconazole
Palonosetron {u} may lead to a major life threatening interaction when taken with {v} Lefamulin
Palonosetron {u} may lead to a major life threatening interaction when taken with {v} Mirtazapine
Palonosetron (Compound) resembles Praziquantel (Compound)
Palonosetron (Compound) binds HTR3A (Gene)
Palonosetron (Compound) is included by Serotonin 3 Receptor Antagonists (Pharmacologic Class)
Palonosetron (Compound) causes Malnutrition (Side Effect)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole
Palonosetron may lead to a major life threatening interaction when taken with Lefamulin
Palonosetron may lead to a major life threatening interaction when taken with Mirtazapine